IGFL2-AS1: A Potential Drug Target and Biomarker (G645553)

Target Name: IGFL2-AS1

NCBI ID: G645553

Other Name(s): IGFL2 antisense RNA 1

IGFL2-AS1: A Potential Drug Target and Biomarker

Introduction

The insulin-like growth factor (IGF) signaling pathway is a critical regulator of cellular growth, development, and survival. IGFL2, a protein that belongs to the IGFL2 family, plays a key role in this pathway. Mutations in the IGFL2 gene have been linked to various diseases, including growth disorders, neurodegenerative diseases, and cancer. In addition, aberrant levels of IGFL2 have also been implicated in several types of cancer, including breast, ovarian, and prostate cancer.

One of the IGFL2 genes, IGFL2-AS1, has recently been identified as a potential drug target and biomarker. This gene has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. Overexpression of IGFL2-AS1 has been linked to cancer cell survival and the development of resistance to anti-cancer drugs.

Drug Target Potential

IGFL2-AS1 has been identified as a potential drug target due to its role in the IGF signaling pathway. IGF signaling is a critical regulator of cellular growth, development, and survival, and IGFL2-AS1 has been shown to play a key role in this pathway. IGFL2-AS1 has been shown to promote the growth and survival of various types of cancer cells, including breast, ovarian, and prostate cancer.

In addition, IGFL2-AS1 has also been shown to contribute to the development of resistance to anti-cancer drugs in cancer cells. Studies have shown that overexpression of IGFL2-AS1 has been linked to the development of resistance to taxane, a common chemotherapy drug for breast and ovarian cancer. This is thought to occur through the inhibition of topoisomerase 2 (T-DNA), a protein that helps ensure the stability of DNA.

Biomarker Potential

IGFL2-AS1 has also been shown to be a potential biomarker for various types of cancer, including breast, ovarian, and prostate cancer. Overexpression of IGFL2-AS1 has also been shown to be associated with the development of various types of cancer, including breast, ovarian, and prostate cancer. In addition, IGFL2-AS1 has also been shown to be overexpressed in various types of cancer, including lung, colon, and skin cancer, which are not typically associated with IGFL2-AS1 overexpression.

Methods

To study the potential drug target and biomarker properties of IGFL2-AS1, several studies have been performed. These studies have focused on the characterization of IGFL2-AS1 expression and its role in the IGF signaling pathway.

One study, published in the journal Cancer Research, showed that IGFL2-AS1 was overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. The study also demonstrated that IGFL2-AS1 was associated with the development of cancer cell resistance to anti-cancer drugs.

Another study, published in the journal Oncology Reports, showed that IGFL2-AS1 was overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. The study also demonstrated that IGFL2-AS1 was associated with the development of cancer cell resistance to anti-cancer drugs.

Conclusion

IGFL2-AS1 has been identified as a potential drug target and biomarker due to its role in the IGF signaling pathway and its association with the development of cancer cell resistance to anti-cancer drugs. Further studies are needed to fully understand the potential of IGFL2- AS1 as a drug

Protein Name: IGFL2 Antisense RNA 1

More Common Targets